The Decision Resources Pharmaview Competitive Assessment

To ensure that our emails get to your inbox, please add Decision_Resources@mail.vresp.com to your email address book or safe senders list.
PLEASE DO NOT REPLY TO THIS EMAIL; CONTACT YOUR ACCOUNT REPRESENTATIVE DIRECTLY.

If this message does not display properly, please click here to launch your browser

Decision Resources Pharmaview Competitive Assessment

Astellas and OSI: Major Japanese Pharma Companies Continue to Upgrade Their U.S. Presence and Oncology Portfolios

— A Pharmaview Competitive Assessment from Decision Resources

Decision Resources is offering an exclusive Pharmaview competitive assessment entitled Astellas and OSI: Major Japanese Pharma Companies Continue to Upgrade Their U.S. Presence and Oncology Portfolios. This session is ONLY available to Pharmaview subscribers.

Please contact us to learn how you can become a Pharmaview subscriber and attend this event.

After being spurned by management, Astellas took its $52.00 tender offer directly to OSI shareholders. Astellas subsequently raised its offer to $57.70 a share, valuing OSI at about $4 billion. Why was Astellas so eager to make this deal, what do they get for their $4 billion investment and what does it mean for their future growth outlook?

Decision Resources’ Pharmaview Analyst Mike Latwis breaks down what this combination means to the pipeline and key drug franchises at Astellas.

In this 20 minute presentation, Mr. Latwis will answer the following questions:

Why is Astellas pursuing OSI at this time?
How does this deal fit into Astellas’s overall corporate strategy?
How does this transaction compare with other recent Japanese pharma deals?
What are the major opportunities and risks in OSI’s portfolio and pipeline?
How well does this deal help position Astellas's drug portfolio for longer-term growth?

Mr. Latwis will conduct a live Q & A session after the presentation.

Registration

Astellas and OSI: Major Japanese Pharma Companies Continue to Upgrade Their U.S. Presence and Oncology Portfolios

June 3, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can become a Pharmaview subscriber and attend this event, please contact us using the information below.

Jackie Jordan at 781-296-2662 or jjordan@dresources.com

Event Details

Date & Time
Thursday, June 3, 2010
10 a.m. ET, 4 p.m. CET

Presentation: 20 minutes

Q & A: 10 minutes

About the Speaker

Michael Latwis, M.B.A., is a corporate analyst for Decision Resources’ Pharmaview team, covering the major pharmaceutical and biotech companies in the U.S. market. The majority of Mr. Latwis’ background is in the financial services industry, with ten years of experience as an equity analyst and buy-side portfolio manager at the Wealth Management Division of Barclays Bank. He received an M.B.A. in finance from Pace University in New York City and an undergraduate degree from Rutgers College in New Jersey.

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.